Related Experiment Videos
[Use of urokinase in acute myocardial infarction]
Insights
Early urokinase treatment for acute myocardial infarction improves clinical outcomes. Delayed administration (after 6 hours) showed no benefit, highlighting the critical timing for thrombolytic therapy effectiveness in heart attack patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality.
- Thrombolytic therapy aims to restore blood flow in AMI.
- The efficacy of urokinase in AMI requires further investigation.
Purpose of the Study:
- To evaluate the clinical effectiveness of urokinase in patients with acute myocardial infarction.
- To determine the impact of treatment timing on clinical outcomes and infarct size.
- To assess the effect of urokinase on venous flow and the fibrinolytic system.
Main Methods:
- Prospective study comparing 88 patients treated with urokinase to 41 controls.
- Precordial mapping using 35 ECG leads to assess necrotic focus.
- Monitoring of clinical course, venous flow, and fibrinolytic system activation.
Main Results:
- Thrombolytic therapy with urokinase initiated within 6 hours of AMI onset improved clinical course.
- Urokinase administered after 6 hours did not improve clinical outcomes, limit infarct size, or reduce mortality.
- A 30% increase in venous flow was observed in 45% of treated patients.
- Intravenous urokinase activated the blood fibrinolytic system, with a trend towards depression the following day.
Conclusions:
- Early administration of urokinase (within 6 hours) is crucial for effective thrombolytic therapy in AMI.
- Delayed treatment does not confer clinical benefits and fails to limit myocardial damage.
- Urokinase enhances venous flow and activates the fibrinolytic system, but timing is paramount for therapeutic success.
Abstract:
Clinical course of the disease and the formation of the necrotic focus (as evidenced by precordial mapping from 35 ECG leads) were assessed in 88 patients with acute myocardial infarction, treated with 1,000,000 IU urokinase, in comparison to 41 untreated control patients. Thrombolytic therapy, started within the first 6 hours of myocardial infarction, was associated with a better clinical course of the disease. Urokinase administration after 6 hours from the onset of the symptoms produced no clinical improvement, did not limit the necrotic focus and failed to reduce mortality, as compared to the controls. The assessment of the efficiency of thrombolytic treatment demonstrated an at least 30% increment of venous flow in 45% of patients. Intravenous urokinase administration was accompanied by an activation of blood fibrinolytic system, and there was a tendency to fibrinolysis depression on the day following the administration.